You are here: Home » 2021 » Archives for April 2021

BitWats release Powerful 5nm ASIC Miners

NEW YORK, April 20, 2021 (GLOBE NEWSWIRE) — Bitwats (www.BitWats.com), a team of technology leaders working relentlessly to bring the latest crypto–mining technology to the public, has just released the market's most powerful and profitable crypto miners. The company's product range currently comprises of BT, DBT, and GBT, three multi–algorithm miners capable of delivering lightening fast hash rate, maximum energy efficiency, and fastest possible return on investment.

All the miners from Bitwats are built around the latest ASIC technology. An ASIC or application–specific integrated circuit is a microchip designed for a special application. Powered by 5nm ASIC chips, the mining rigs from Bitwats offer extraordinary hash rates and energy efficiency for mining bitcoin, litecoin, ethereum, and monero. As a result, the profitability of these miners is second to none in the current crypto market.

DBT offers hash rates of 750 TH/s, 70 GH/s, 5 GH/s, and 5 MH/s, for bitcoin, litecoin, ethereum, and monero respectively. On the other hand, for GBT Miner, the hash power in the same order are 2250 TH/s, 210 GH/s, 15 GH/s, and 15 MH/s. The power consumptions for these two units are 900W and 2200W respectively

Bitwats designed its crypto miners with the goal of making crypto mining easy and profitable for all, including the newbies. Once these miners are delivered, anyone can start mining simply by connecting the unit to a power socket and accessing it through WiFi or cable, and entering the pool data. Users also have the option of joining Bitwats' own mining pool that has a 0% fee. Also, the company covers the delivery and custom fees for its customers.

To find out more, please visit https://www.bitwats.com

About Bitwats: Bitwats was founded in 2016 by a team of technology leaders with a track record of working for the world's most prodigious companies in the past. Dedicated to bringing the latest crypto–mining technology to the public, the company has recently introduced its exquisite line of advanced ASIC miners. Unlike most other crypto mining hardware manufacturers, Bitwats continuously works towards making crypto mining easy and profitable for all regardless of their experience and knowledge.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f3e97db4–cc4e–4348–9ef5–48fb7acc0b0f

Contact:
Daniel Lotin
marketing@bitwats.com
+1 (347) 905–5614


GLOBENEWSWIRE (Distribution ID 8220346)

The NOBLE Registry – An International Collaboration to Develop iPSMA SPECT Imaging for Prostate Cancer

BRUSSELS, Belgium and MELBOURNE, Australia, April 20, 2021 (GLOBE NEWSWIRE) — The Oncidium Foundation, a non–profit organisation created to promote and support the development of radiopharmaceuticals for better patient access, and Telix Pharmaceuticals Limited ("Telix'), a radiopharmaceutical company developing diagnostic and therapeutic products ("theranostics') using Molecularly Targeted Radiation (MTR), are pleased to announce the launch of the NOBLE Registry, an international clinical collaboration for the development of 99mTc–iPSMA SPECT imaging for prostate cancer, and the dosing of the first patient at the University College Hospital, Ibadan, Nigeria.

Prostate cancer is the second most frequent cancer diagnosis in men and the fifth leading cause of cancer death worldwide1. Early detection can significantly reduce the mortality rate and in recent years much attention has focused on PSMA2 as a target for imaging and therapy using radionuclides for prostate cancer.

PSMA positron emission tomography (PSMA PET) is an emerging standard of care in prostate cancer imaging.3 Unfortunately, globally, not every patient will have access to a PSMA PET scan when indicated. The NOBLE (Nobody Left Behind) Registry aims to demonstrate that PSMA single photon emission computed tomography (PSMA SPECT), a diagnostic imaging technology widely available in healthcare facilities throughout the world,4 is a cost–effective and viable alternative. Enhancing global availability and access to 99mTc–iPSMA SPECT imaging has the potential to provide accurate diagnosis and staging to patients with prostate cancer regardless of where they reside.

The NOBLE Registry Committee, made up of globally recognized investigators at eight sites worldwide,5 aims to deliver and publish real–world evidence and clinical practice guidelines related to SPECT imaging and prostate cancer.

"The advancement of PSMA directed diagnostics and therapeutics in prostate cancer is helping to extend life and improve treatment outcomes in men with prostate cancer," said Dr. Batool Albalooshi, Chair of the NOBLE Registry Committee. "However, millions of men do not have access to PET imaging. For this reason, it is our aspiration to develop a powerful, affordable, and widely available alternative imaging tool by using iPSMA SPECT technology."

"Introducing PSMA has been difficult and exciting for the team at Ibadan. When I think of the opportunities for prostate cancer research and management without PET, I am motivated to get past the challenges. I look forward to a better future, with nobody left behind," said Dr. Akintunde Orunmuyi, Investigator at the University College Hospital, Ibadan, Nigeria, where the first patient is being dosed.

The NOBLE Registry has been initiated and is co–supported by the Oncidium Foundation and Telix Pharmaceuticals. "We aim to enable patients with prostate cancer, regardless of origin, technology access or financial situation, to access PSMA SPECT imaging for accurate diagnosis and treatment planning," said Rebecca Lo bue, General Manager of the Oncidium Foundation.

"We are honoured to support the launch of the NOBLE Registry, which represents the very essence of our belief that every patient deserves access to the benefits of nuclear medicine. We wish to thank the Oncidium Foundation for their support and partnership, as well as the expert global clinical leadership team led by Dr. Albalooshi. Above all, we are grateful to the patients that will make this registry study possible and, in doing so, help to deliver an important milestone toward improving access to this important technology." said Dr. Christian Behrenbruch, Chief Executive Officer of Telix Pharmaceuticals.

About the Oncidium Foundation
The Oncidium Foundation was created in 2011 by Dr. Richard Zimmermann. The Foundation's priorities include promoting awareness about radiotherapeutics among patients and physicians, investing in research and scholarships, supporting, and financing the development of new radiopharmaceuticals for therapy, supporting clinical best practice, and improving access to patients. https://www.oncidiumfoundation.org/

About Telix Pharmaceuticals Limited

Telix is a clinical–stage radiopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical–stage products that address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter @TelixPharma and LinkedIn.

None of Telix's products have received a marketing authorisation in any jurisdiction.

Oncidium Foundation Contact Telix Media Contact
Rebecca Lo bue
Oncidium Foundation
General Manager
Email: rebecca@oncidium–life.org 		Dr. Stewart Holmstrom
Telix Pharmaceuticals Limited
Director of Corporate Communications
Email: Stewart.Holmstrom@Telixpharma.com

_______________________

1 Globocan 2020.
2 Prostate–specific membrane antigen – a protein expressed on the surface of prostate cancer cells.
3 Hofman M, et al. The Lancet 2020; Trabulsi E, et al. Journal of Clinical Oncology 2020.
4 In 2020 there were an estimated 25,500 SPECT and 6,700 PET cameras installed worldwide (Source: MEDraysintell).
5 Australia, Egypt, India, Mexico, Nigeria, South Africa, Turkey, United Arab Emirates.


GLOBENEWSWIRE (Distribution ID 8220274)

Entera Announces Ron Mayron, a Global Pharma Leader, Joins its Board of Directors

BOSTON and JERUSALEM, April 20, 2021 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced that Ron Mayron has joined its Board of Directors. Mr. Mayron is taking the seat of Zeev Bronfeld, a Founder of Entera, who served on its Board since 2010, and was Chairman from 2014 to 2016.

Mr. Mayron is global healthcare specialist who serves on the boards of numerous public and privately held pharma and medical device companies in Israel, including DNA BioMedical Solutions, Innocan Pharma, and IceCure Medical. His prior executive experience includes several leadership positions culminating in CEO of Teva Israel & Africa and CEO of S.L.E. His expertise within healthcare includes M&A, integration and implementation, global business development, global operations, and supply chain management. He earned a B.Sc. from Ben–Gurion University, an MBA from the University of Tel Aviv, and attended several programs at Insead University Fontainebleu, France and the Massachusetts Institute of Technology, Boston. Mr. Mayron served as an Officer in the Israeli army achieving the rank of Major.

Jerry Lieberman, Entera's Chairman commented, "We welcome Ron to the Board as we advance our pipeline of oral drug candidates for biologics and active ingredients that were previously only administrated through injection. Ron's deep knowledge in the management and logistics of commercialized pharma products at Teva, as well as his vast experience serving on the boards of over a dozen private and publicly traded healthcare companies are assets to Entera."

"On behalf of the entire Board, I extend gratitude to Zeev for his insight as a Founder of Entera, his leadership as a Board member, and his twelve years of service to the Company. His contributions have helped Entera become a NASDAQ listed company and a global leader in the oral delivery of proteins. We wish him well," Mr. Lieberman concluded.

About Entera Bio

Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company's proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Company's most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in Phase 2 clinical development. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. For more information on Entera Bio, visit www.enterabio.com.

Forward Looking Statements

Various statements in this release are "forward–looking statements" under the securities laws. Words such as, but not limited to, "anticipate," "believe," "can," "could," "expect," "estimate," "design," "goal," "intend," "may," "might," "objective," "plan," "predict," "project," "target," "likely," "should," "will," and "would," or the negative of these terms and similar expressions or words, identify forward–looking statements. Forward–looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward–looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved.

Important factors that could cause actual results to differ materially from those reflected in Entera's forward–looking statements include, among others: changes in our interpretation of the complete3–month biomarker data from the ongoing Phase 2 clinical trial of EB613, the timing of data readouts from the ongoing Phase 2 clinical trial of EB613, the full results of the Phase 2 clinical trial of EB613, which is still ongoing and our analysis of those full results, the FDA's interpretation and review of our results from and analysis of our Phase 2 trial of EB613, unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; a possible suspension of the Phase 2 clinical trial of EB613 for clinical or data–related reasons; the impact of COVID–19 on Entera's business operations including the ability to collect the necessary data from the Phase 2 trial of EB613; the potential disruption and delay of manufacturing supply chains, loss of available workforce resources, either by Entera or its collaboration and laboratory partners, due to travel restrictions, lay–offs or forced closures or repurposing of hospital facilities; impacts to research and development or clinical activities that Entera is contractually obligated to provide, such as those pursuant to Entera's agreement with Amgen; overall regulatory timelines, if the FDA or other authorities are closed for prolonged periods, choose to allocate resources to review of COVID–19 related drugs or believe that the amount of Phase 2 clinical data collected are insufficient to initiate a Phase 3 trial, or a meaningful deterioration of the current political, legal and regulatory situation in Israel or the United States; the availability, quality and timing of the data from the Phase 2 clinical trial of EB613 in osteoporosis patients; the ability to find a dose that demonstrates the comparability of EB613 to FORTEO in the ongoing Phase 2 clinical trial of EB613; the size and growth of the potential market for EB613 and Entera's other product candidates including any possible expansion of the market if an orally delivered option is available in addition to an injectable formulation; the scope, progress and costs of developing Entera's product candidates including EB612 and GLP–2; Entera's reliance on third parties to conduct its clinical trials; Entera's expectations regarding licensing, business transactions and strategic collaborations; Entera's operation as a development stage company with limited operating history; Entera's ability to continue as a going concern absent access to sources of liquidity; Entera's expectations regarding its expenses, revenue, cash resources, liquidity and financial condition; Entera's ability to raise additional capital; Entera's interpretation of FDA feedback and guidance and how such guidance may impact its clinical development plans; Entera's ability to obtain and maintain regulatory approval for any of its product candidates; Entera's ability to comply with Nasdaq's minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States; Entera's intellectual property position and its ability to protect its intellectual property; and other factors that are described in the "Special Note Regarding Forward–Looking Statements," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Entera's annual and current filings which are on file with the SEC and available free of charge on the SEC's website at http://www.sec.gov. Additional factors may be set forth in those sections of Entera's Annual Report on Form 20–F for the year ended December 31, 2020, filed with the SEC in the first quarter of 2021. In addition to the risks described above and in Entera's annual report on Form 20–F and current reports on Form 6–K and other filings with the SEC, other unknown or unpredictable factors also could affect Entera's results. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no assurance can be given that the outcomes stated in such forward–looking statements and estimates will be achieved.

All written and verbal forward–looking statements attributable to Entera or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Entera cautions investors not to rely too heavily on the forward–looking statements Entera makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Entera undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward–looking statements, whether as a result of new information, future events or otherwise.

Contact:

Spiros Jamas, CEO
Tel: +001 617–362–3579
spiros@enterabio.com


GLOBENEWSWIRE (Distribution ID 8220199)

CoreCard® Business Update: CoreCard partners with Al Ansari Exchange to offer multi-currency prepaid card processing in the UAE

DUBAI, United Arab Emirates, April 19, 2021 (GLOBE NEWSWIRE) — CoreCard Software, DMCC. (a subsidiary of Intelligent Systems Corporation [NYSE American: INS]), the leading international provider of innovative prepaid and credit technology solutions and processing services to the financial technology and services market, announced today a partnership with Al Ansari Exchange, the UAE–based foreign exchange and worldwide money transfer company.

Under this partnership CoreCard is providing prepaid card processing services for the Al Ansari Exchange Visa Platinum Multi–currency travel card. This card can be used at any merchant worldwide that accepts Visa and can be loaded with any of seventeen different currencies making it the smartest, safest and most convenient way to travel whilst enjoying a wide range of benefits and exclusive offers.

This deployment also showcases CoreCard's ability to host its processing services in the cloud which allowed reduced deployment times whilst achieving the highest standards of resilience and the ability to easily scale to match a fast–growing business.

Mohammad Bitar, Deputy Chief Executive Officer, Al Ansari Exchange, said: "Al Ansari Exchange puts great efforts into providing world–class services to its customers using the most advanced technologies and innovative solutions. We are pleased to collaborate with a modern platform such as CoreCard and integrate their technology into our systems to further enhance our customers' experience when using the Al Ansari Exchange Travel Card."

Lee Blair, General Manager for CoreCard in Dubai said, "This is a great day for the new CoreCard Dubai office. We are thrilled to bring CoreCard's market leading platform and processing capabilities into the region and are proud to be working with Al Ansari Exchange to provide such an exciting product to their customers."

About CoreCard

CoreCard Software, a leading provider of card management systems and processing services, offers an array of account management solutions to support the complex requirements of the evolving global financial services industry. CoreCard software solutions provide the market's most feature–rich and flexible platform for processing and managing a full range of card products including prepaid/stored–value, multi–currency wallets, virtual card issuing, instant financing, small loans, point of sale loans, fleet, credit, debit, commercial, government, healthcare and private–label cards as well as accounts receivable and loans. CoreCard is headquartered in Norcross, GA with additional offices in India, the United Arab Emirates and Romania. CoreCard is a subsidiary of Intelligent Systems Corporation [NYSE AMERICAN: INS].

For more information, email solutions@corecard.com, or visit www.corecard.com

About Al Ansari Exchange

Al Ansari Exchange, a leading exchange company in the UAE with the largest branch network, was founded in 1996. Its first branch started as an offshoot of a flourishing general trading business by the Al Ansari family, established primarily to meet the foreign exchange and remittance needs of the Al Ansari family's trading partners and customers.

The company has expanded to over 190 branches nationwide, making it the largest and most popular exchange company in the UAE today. It employs over 2,500 multilingual staff who serve more than 2.5 million customers every month. It is one of the first exchange houses in the country to have integrated innovation and digital technology into its systems and platforms. Its efforts culminated with the launch of Al Ansari Exchange Mobile App in 2018. Currently, the App is the highest–rated app among the exchange houses in the UAE on Google Play and the Apple Store with over one million downloads to date and more than 200,000 active users monthly.

For more information, please visit www.alansariexchange.com


GLOBENEWSWIRE (Distribution ID 8219366)

Zoom Announces $100 Million Zoom Apps Fund

SAN JOSE, Calif., April 19, 2021 (GLOBE NEWSWIRE) — Zoom Video Communications, Inc. (NASDAQ: ZM) today announced the Zoom Apps Fund, a new $100 million venture fund created to stimulate growth of Zoom's ecosystem of Zoom Apps, integrations, developer platform, and hardware. Portfolio companies will receive initial investments between $250,000 and $2.5 million to build solutions that will become core to how Zoom customers meet, communicate, and collaborate. Zoom Apps, announced at Zoomtopia 2020, are leading applications that will bring productivity and engaging experiences directly into the Zoom platform.

Dozens of Zoom Apps are currently in development and are an important component in building the future of video communications. The Zoom Apps Fund will invest in developer partners with viable products and early market traction that will provide valuable and engaging experiences to our customers.

"I founded Zoom in 2011, nearly ten years ago. Without the support of early investors, Zoom would not be what it is today," said Eric S. Yuan, Founder and CEO of Zoom. "What I've learned over the past year is that we need to keep meetings productive and fun. My hope is that the Zoom Apps Fund will help our customers meet happier and collaborate even more seamlessly, and at the same time help entrepreneurs build new businesses as our platform evolves."

To learn more about the Zoom Apps Fund visit zoom.com/fund and read our recent blog post.

About Zoom
Zoom is for you. We help you express ideas, connect to others, and build toward a future limited only by your imagination. Our frictionless communications platform is the only one that started with video as its foundation, and we have set the standard for innovation ever since. That is why we are an intuitive, scalable, and secure choice for individuals, small businesses, and large enterprises alike. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Visit zoom.com and follow @zoom.

Zoom Press Contact
Colleen Rodriguez
Global PR Lead
press@zoom.us


GLOBENEWSWIRE (Distribution ID 8218984)

NeoTX Announces FDA Clearance of IND for Phase 2 Clinical Trial of Naptumomab Estafenatox (NAP), its lead Tumor Targeted Superantigen Candidate

REHOVOT, Israel, April 19, 2021 (GLOBE NEWSWIRE) — NeoTX Therapeutics (NeoTX), a clinical–stage immuno–oncology company, announced today that it received clearance from the U.S. Food and Drug Administration (FDA) for the Company's Investigational New Drug (IND) application for naptumomab estafenatox (NAP). NeoTX is developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. NAP, the company's lead TTS molecule, binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells. NAP has demonstrated preliminary safety and anti–tumor activity in early–stage clinical trials in solid tumors.

"This FDA clearance is an exciting milestone for NeoTX," said Asher Nathan, Ph.D., chief executive officer of NeoTX. "Preclinical and preliminary clinical studies have demonstrated that NAP has potential in combination with other treatment modalities. Non–small cell lung cancer is one of the deadliest cancers, and we are looking forward to assessing NAP in the clinic in combination with chemotherapy as a potential new treatment option after failure of current standards of care."

The Phase 2a open label trial will evaluate NAP in combination with docetaxel in 35 patients with checkpoint inhibitor pretreated, advanced or metastatic non–small cell lung cancer. The primary endpoint is objective response rate as measured by RECIST 1.1 criteria. The trial will also evaluate safety, duration of response, progression free survival, overall survival, pharmacokinetics and pharmacodynamics.

About NeoTX
NeoTX is a clinical–stage immuno–oncology company which is developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. TTS binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells that are then redirected from the periphery to the tumor to mount an effective response. The company's lead TTS molecule, naptumomab estafenatox (NAP) is currently in clinical development for advanced solid tumors. For more information, please visit www.neotx.com.

Media Contact:
Cait Williamson, Ph.D.
LifeSci Communications
(646) 751–4366
cait@lifescicomms.com


GLOBENEWSWIRE (Distribution ID 8218939)

Nyxoah Announces Submission of Draft Registration Statement For Proposed Public Listing in the United States

REGULATED INFORMATION
INSIDE INFORMATION

Nyxoah Announces Submission of Draft Registration Statement For Proposed Public Listing in the United States

Mont–Saint–Guibert, Belgium "" 19 April 2021 "" Nyxoah SA (Euronext Brussels: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that it has confidentially submitted a draft Registration Statement on Form F–1 to the Securities and Exchange Commission (the “SEC”) relating to the proposed public offering of its ordinary shares in the United States. The number of ordinary shares to be offered and the price for the proposed offering have not yet been determined. The public offering is expected to take place after the SEC completes its review process, subject to market and other conditions.

This announcement is being made pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933, as amended (the “Securities Act”).

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities, if at all, will be made in accordance with the registration requirements of the Securities Act.

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014).

Contacts:
Nyxoah
Fabian Suarez, Chief Financial Officer
fabian.suarez@nyxoah.com
+32 10 22 24 55

Gilmartin Group
Vivian Cervantes
vivian.cervantes@gilmartinir.com

Attachment


GLOBENEWSWIRE (Distribution ID 1000479118)

Kibali Goldmines Rejects SOKIMO Claim

KINSHASA, Democratic Republic of the Congo, April 18, 2021 (GLOBE NEWSWIRE) — Kibali Goldmines SA (Kibali) said today it had learned that SOKIMO SA was attempting for the second time to extort certain benefits from the company by filing new proceedings with the commercial court in Kinshasa. SOKIMO is a 10% shareholder in the Kibali gold mine which is operated by 45% owner Barrick Gold Corporation (NYSE:GOLD) (TSX:ABX) with the remaining 45% held by AngloGold Ashanti.

Kibali said SOKIMO had withdrawn its first claim of this kind after it had been shown to be without foundation. Kibali also rejects the current proceedings on the basis that it was similarly spurious and without substance, and would seek its dismissal as it had done with the previous claim.

Kibali has operated for the past 12 years under a joint venture agreement with a clear dispute resolution mechanism which in these instances had been ignored by SOKIMO, the company said.

Enquiries:
President and CEO
Mark Bristow
+1 647 205 7694
+44 788 071 1386		 Investor and Media Relations
Kathy du Plessis
+44 20 7557 7738
Email: barrick@dpapr.com
Website: www.barrick.com


GLOBENEWSWIRE (Distribution ID 8218911)

Leaders to Gather at Coach Africa’s ‘African Excellence Summit 2021’ to Share Vision for the Future of Africa

KAMPALA, Uganda., April 16, 2021 (GLOBE NEWSWIRE) — Coach Africa is proud to welcome attendees from all corners of the continent for Africa's #1 virtual business summit – African Excellence Summit 2021.

The African Excellence Summit is an initiative of Coach Africa which aims to enhance African excellence by promoting a purpose–first mindset. With over 30 speakers, the summit aims to gather leaders from the public, private and development sectors to drive Africa's transition towards a purpose–first economy anchored on excellence and leadership.

"Africa is going through a period of change," says Dr. Norah Njuba Bwaya (PCC), Founder of Coach Africa Limited and executive coach with over 30 years of working experience. "The time for Africa is now. We're excited to be bringing together entrepreneurs, policy and decision–makers from across the continent to showcase a new vision for the future while demonstrating the significance and value of a purpose–first economy."

The three–day summit provides organizations, coaches and entrepreneurs a platform for discussion around key themes related to Africa's development, including:

  • 22nd of April: Purpose–First: Creating an Africa Where Everyone Wins
  • 23rd of April: The role of coaches/coaching in advancing the leadership cause for African Development
  • 24th of April: How to monetize your genius? The Opportunities for Building your own virtual empire, your message matters!

Registration is still open for the African Excellence Summit 2021, but remaining space is filling up quickly. Visit www.africanexcellencesummit.com to learn more.

About Coach Africa

Coach Africa supports African Excellence by building exceptional leaders: Leaders in different capacities and walks of life who are walking the path of reimagining what can be; leaders who stand for the betterment of their individual growth and collectively as a Continent; and leaders who use their transformational journey to help transform society. Our purpose is to build leaders with the capacity to exponentially inspire others. Leaders that are motivated by passion, generated by vision, produced by a conviction and ignited by a purpose. We believe African people both on the Continent and in the diaspora, share not merely a common history, but a common destiny.

Coach Africa … where Excellence is past, present and the future!

For More information, contact: Eileen Walusimbi Oloya
Director Coach Africa Academy eileen@coachafrica.org
www.africanexcellencesummit.com


GLOBENEWSWIRE (Distribution ID 1000478835)

NetJets Shares First Biannual Global Sustainability Program Progress Update

COLUMBUS, Ohio, April 15, 2021 (GLOBE NEWSWIRE) — NetJets, the leader in private aviation with more than 760 aircraft worldwide, today releases its first biannual update following the launch of its expanded Global Sustainability Program in October 2020. Since the program announcement, NetJets has taken its commitment to sustainability a step further, acquiring a stake in WasteFuel , a next generation waste–to–fuel business that transforms landfill waste into sustainable aviation fuel (SAF). NetJets will also purchase 100 million gallons of SAF over the next decade. This represents one of the largest SAF offtakes in the aviation industry and by far the largest in private aviation.

In addition to sustainable fuel, NetJets' initiative focuses on consumer and corporate carbon offsetting. This includes offsetting NetJets' administrative and training flights, as well as its two corporate offices in Columbus, Ohio, which are now carbon neutral.

The following metrics are highlights of these collective efforts in the U.S. over the last six months:

  • A 61% increase in Blue Skies enrollment
    • The Blue Skies program encourages Owners worldwide to take responsibility for the environmental impact of their flight by seamlessly purchasing the equivalent amount of carbon credits to ensure their flight activity is carbon neutral
  • Approximately 750,000 nautical miles flown with SAF
  • 38,543 metric tons of CO2 offset
  • 7,650 carbon neutral flight hours purchased

NetJets Europe, which has been carbon neutral since 2012, offset 4,724 metric tons of carbon from October 2020 through February 2021 and over 1 million metric tons total. NetJets Europe will begin purchasing SAF in 2021.

"Our worldwide sustainability efforts continue to be a source of pride and passion for us at NetJets and a key business priority in 2021 and beyond," said Brad Ferrell, Executive Vice President of Administrative Services. "Our financial and operational commitments, to SAF in particular, not only push competitors to take a stance on the issue but also help guarantee the continued availability of sustainable fuel for the larger aviation industry. This is just the beginning of our journey, and we are invigorated to further our progress as the leader in sustainable private aviation."

A subsidiary of Berkshire Hathaway, NetJets aligns its Global Sustainability Program with the holding company's commitment to the U.N. Sustainable Development Goals. To follow NetJets' sustainability progress, visit https://www.netjets.com/en–us/sustainability.

About NetJets

Beginning as the first private jet charter and management company, NetJets has led the industry for 55+ years. Then in 1986, they revolutionized it with the concept of shared ownership and proceeded to build the largest, most diverse private jet fleet in the world. Today, NetJets is proud to be a Berkshire Hathaway company known for its unwavering commitment to safety, service, and unmatched global access. NetJets' industry–leading scale and business model offer NetJets and its Owners dependable financial sustainability unlike any other in the industry. For these reasons and many more, NetJets will continue to be the favored choice of the world's most discerning travelers for generations to come. For more information about the world's most reliable and trusted aviation company, please visit netjets.com.


GLOBENEWSWIRE (Distribution ID 8217777)